Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation

Maro Ohanian; Carlos Bueso-Ramos; Chi Young Ok; Pei Lin; Keyur Patel; Mona Lisa Alattar; Joseph D. Khoury; Uri Rozovski; Zeev Estrov; Yang O. Huh; Jorge Cortes; Lynne V. Abruzzo

doi:10.1016/j.cancergen.2015.06.004

Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation

Maro Ohanian, Carlos Bueso-Ramos, Chi Young Ok, Pei Lin, Keyur Patel, Mona Lisa Alattar, Joseph D. Khoury, Uri Rozovski, Zeev Estrov, Yang O. Huh, Jorge Cortes, Lynne V. Abruzzo

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Little is known about MYC dysregulation in myeloid malignancies, and the authors were unable to find published studies that evaluated MYC protein expression in primary cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Herein, we describe the clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic findings in two MDS/AML cases that contained both MYC rearrangement and the JAK2 V617F mutation. We also demonstrate MYC protein expression by immunohistochemistry in both patients.

Original language	English (US)
Pages (from-to)	571-574
Number of pages	4
Journal	Cancer Genetics
Volume	208
Issue number	11
DOIs	https://doi.org/10.1016/j.cancergen.2015.06.004
State	Published - Nov 2015
Externally published	Yes

Keywords

Acute myeloid leukemia
Blastic plasmacytoid dendritic cell neoplasm
JAK2 V617F mutation
MYC

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1016/j.cancergen.2015.06.004

Cite this

@article{3850bcffcdd143eba8b91528d8da5c48,

title = "Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation",

abstract = "Little is known about MYC dysregulation in myeloid malignancies, and the authors were unable to find published studies that evaluated MYC protein expression in primary cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Herein, we describe the clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic findings in two MDS/AML cases that contained both MYC rearrangement and the JAK2 V617F mutation. We also demonstrate MYC protein expression by immunohistochemistry in both patients.",

keywords = "Acute myeloid leukemia, Blastic plasmacytoid dendritic cell neoplasm, JAK2 V617F mutation, MYC",

author = "Maro Ohanian and Carlos Bueso-Ramos and Ok, {Chi Young} and Pei Lin and Keyur Patel and Alattar, {Mona Lisa} and Khoury, {Joseph D.} and Uri Rozovski and Zeev Estrov and Huh, {Yang O.} and Jorge Cortes and Abruzzo, {Lynne V.}",

note = "Publisher Copyright: {\textcopyright} 2015 .",

year = "2015",

month = nov,

doi = "10.1016/j.cancergen.2015.06.004",

language = "English (US)",

volume = "208",

pages = "571--574",

journal = "Cancer Genetics",

issn = "2210-7762",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation

AU - Ohanian, Maro

AU - Bueso-Ramos, Carlos

AU - Ok, Chi Young

AU - Lin, Pei

AU - Patel, Keyur

AU - Alattar, Mona Lisa

AU - Khoury, Joseph D.

AU - Rozovski, Uri

AU - Estrov, Zeev

AU - Huh, Yang O.

AU - Cortes, Jorge

AU - Abruzzo, Lynne V.

PY - 2015/11

Y1 - 2015/11

N2 - Little is known about MYC dysregulation in myeloid malignancies, and the authors were unable to find published studies that evaluated MYC protein expression in primary cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Herein, we describe the clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic findings in two MDS/AML cases that contained both MYC rearrangement and the JAK2 V617F mutation. We also demonstrate MYC protein expression by immunohistochemistry in both patients.

AB - Little is known about MYC dysregulation in myeloid malignancies, and the authors were unable to find published studies that evaluated MYC protein expression in primary cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Herein, we describe the clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic findings in two MDS/AML cases that contained both MYC rearrangement and the JAK2 V617F mutation. We also demonstrate MYC protein expression by immunohistochemistry in both patients.

KW - Acute myeloid leukemia

KW - Blastic plasmacytoid dendritic cell neoplasm

KW - JAK2 V617F mutation

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84947870442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947870442&partnerID=8YFLogxK

U2 - 10.1016/j.cancergen.2015.06.004

DO - 10.1016/j.cancergen.2015.06.004

M3 - Article

C2 - 26382622

AN - SCOPUS:84947870442

SN - 2210-7762

VL - 208

SP - 571

EP - 574

JO - Cancer Genetics

JF - Cancer Genetics

IS - 11

ER -

Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this